国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (11): 657-660.doi: 10.3760/cma.j.issn.1673-422X.2018.11.004

• 论著 • 上一篇    下一篇

芳香化酶抑制剂治疗乳腺癌患者骨关节疼痛发生情况及生命质量调查

邱霞，徐明英   

  1. 642150 四川省隆昌市人民医院妇产科
  • 出版日期:2018-11-08 发布日期:2018-12-21
  • 通讯作者: 邱霞，Email: hhve45@163.com E-mail:hhve45@163.com

Investigation of the occurrence of arthralgia and the quality of life of patients with breast cancer treated with aromatase inhibitors

Qiu Xia, Xu Mingying   

  1. Department of Gynaecology and Obstetrics, Longchang Municipal People′s Hospital of Sichuan Province, Longchang 642150, China
  • Online:2018-11-08 Published:2018-12-21
  • Contact: Qiu Xia, Email: hhve45@163.com E-mail:hhve45@163.com

PDF

594

摘要： 目的 分析芳香化酶抑制剂治疗乳腺癌患者骨关节疼痛发生情况，并评估骨关节疼痛对患者生命质量的影响。方法 选择我院2013年12月至2015年12月收治的187例采用芳香化酶抑制剂进行治疗的乳腺癌患者，视觉模拟评分法评估患者骨关节疼痛发生情况及其疼痛程度，SF-36生命质量调查量表评估患者生命质量。分析患者骨关节疼痛的发生情况。比较发生与未发生骨关节疼痛、不同骨关节疼痛程度乳腺癌患者的生命质量。结果 187例患者中骨关节疼痛发生率为77.5%（145/187），其中轻度疼痛为30.3%（44/145）、中度疼痛为40.0%（58/145）、重度疼痛为29.7%（43/145）。发生骨关节疼痛患者的生理职能（16.73±7.34∶39.73±12.54；t=9.18，P=0.02）、生理功能（53.63±12.91∶77.18±9.82；t=7.49，P=0.04）、精神健康（53.18±14.76∶75.14±17.21；t=14.96，P=0.01）、情感职能（46.23±14.30∶68.75±15.93；t=12.17，P=0.02）、躯体疼痛（40.35±18.49∶91.48±19.67；t=16.28，P=0.01）、社会功能（60.14±12.57∶89.22±10.16；t=13.07，P=0.02）、总体健康（45.52±14.61∶60.78±18.45；t=15.77，P=0.01）、活力（55.31±13.69∶68.22±18.43；t=15.84，P=0.01）的生命质量评分均低于未发生骨关节疼痛者，差异均有统计学意义；不同骨关节疼痛程度乳腺癌患者的生理职能（F=6.67，P=0.03）、生理功能（F=10.94，P=0.02）、精神健康（F=11.32，P=0.02）、情感职能（F=11.49，P=0.02）、躯体疼痛（F=15.71，P=0.01）、社会功能（F=14.92，P=0.01）、总体健康（F=9.98，P=0.02）、活力（F=7.36，P=0.03）的生命质量评分差异均有统计学意义。结论 芳香化酶抑制剂治疗乳腺癌时较易发生骨关节疼痛，骨关节疼痛及其严重程度可影响患者的生命质量。

关键词: 乳腺肿瘤, 关节痛, 生命质量, 芳香化酶抑制剂

Abstract: Objective To analyze the occurrence of arthralgia in patients with breast cancer treated with aromatase inhibitors, and to evaluate the impact of arthralgia on patients′ quality of life. Methods One hundred and eighty seven patients with breast cancer treated with aromatase inhibitors in our hospital from December 2013 to December 2015 were selected. The occurrence and severity of arthralgia in patients were evaluated by using visual analogue scale method. The 36-item short-form health survey (SF-36) was used to evaluate patients′ quality of life. The occurrence of arthralgia in patients was analyzed. In addition, the quality of life of breast cancer patients with and without arthralgia and those with different degree of arthralgia was compared. Results The incidence of arthralgia was 77.5% (145/187) among 187 patients, of which 30.3% was mild (44/145), 40.0% was moderate (58/145) and 29.7% was severe (43/145). The scores of the role-physical (16.73±7.34 vs. 39.73±12.54; t=9.18, P=0.02), physiological function (53.63±12.91 vs. 77.18±9.82; t=7.49, P=0.04), mental health (53.18±14.76 vs. 75.14±17.21; t=14.96, P=0.01), role-emotional (46.23±14.30 vs. 68.75±15.93; t=12.17, P=0.02), bodily pain (40.35±18.49 vs. 91.48±19.67; t=16.28, P=0.01), social function (60.14±12.57 vs. 89.22±10.16; t=13.07, P=0.02), general health (45.52±14.61 vs. 60.78±18.45; t=15.77, P=0.01) and vitality (55.31±13.69 vs. 68.22±18.43; t=15.84, P=0.01) of patients with arthralgia were all lower than those of patients without arthralgia, with statistically significant differences. The scores of the role-physical (F=6.67, P=0.03), physiological function (F=10.94, P=0.02), mental health (F=11.32, P=0.02), role-emotional (F=11.49, P=0.02), bodily pain (F=15.71, P=0.01), social function (F=14.92, P=0.01), general health (F=9.98, P=0.02) and vitality (F=7.36, P=0.03) of different degree of arthralgia in patients with breast cancer had also statistical significance differences. Conclusion Arthralgia is more likely to occur in the treatment of breat cancer with aromatase inhibitors. Arthralgia and its severity can affect the patients′ quality of life.

Key words: Breast neoplasms, Arthralgia, Quality of life, Aromatase inhibitor